Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan and Pucotenlimab in Advanced Cholangiocarcinoma
NCT07105852Phase 2Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, pucotenlimab in cholangiocarcinoma (CCA), sponsored by Sir Run-Run Shaw Hospital. Started Jul 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecanpucotenlimab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07105852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07105852.